I
Ibrahim Yakoub-Agha
Researcher at Lille University of Science and Technology
Publications - 615
Citations - 15645
Ibrahim Yakoub-Agha is an academic researcher from Lille University of Science and Technology. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 55, co-authored 489 publications receiving 11649 citations. Previous affiliations of Ibrahim Yakoub-Agha include university of lille & Hospital General Universitario Gregorio Marañón.
Papers
More filters
Journal ArticleDOI
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau,Michel Attal,Philippe Moreau,Catherine Charbonnel,Frédéric Garban,Cyrille Hulin,Serge Leyvraz,Mauricette Michallet,Ibrahim Yakoub-Agha,Laurent Garderet,Gerald Marit,Lucienne Michaux,Laurent Voillat,Marc Renaud,Bernard Grosbois,Gaelle Guillerm,Lotfi Benboubker,Mathieu Monconduit,Catherine Thieblemont,Philippe Casassus,Denis Caillot,Anne-Marie Stoppa,Jean-Jacques Sotto,Marc Wetterwald,Charles Dumontet,Jean-Gabriel Fuzibet,Isabelle Azais,Véronique Dorvaux,Marc Zandecki,Régis Bataille,Stephane Minvielle,Jean-Luc Harousseau,Thierry Facon,Claire Mathiot +33 more
TL;DR: In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Thierry Facon,Jean Yves Mary,Cyrille Hulin,Lotfi Benboubker,Michel Attal,Brigitte Pegourie,Marc Renaud,Jean Luc Harousseau,Gaelle Guillerm,Carine Chaleteix,Mamoun Dib,Laurent Voillat,Hervé Maisonneuve,Jacques Troncy,Véronique Dorvaux,Mathieu Monconduit,Claude Martin,Philippe Casassus,Jérôme Jaubert,H. Jardel,Chantal Doyen,Brigitte Kolb,Bruno Anglaret,Bernard Grosbois,Ibrahim Yakoub-Agha,Claire Mathiot,Hervé Avet-Loiseau +26 more
TL;DR: The results of this trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma.
Journal ArticleDOI
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi,Larry D Anderson,Nina Shah,Deepu Madduri,Jesus G. Berdeja,Sagar Lonial,Noopur Raje,Yi Lin,David S. Siegel,A. Oriol,Philippe Moreau,Ibrahim Yakoub-Agha,Michel Delforge,Michele Cavo,Hermann Einsele,Hartmut Goldschmidt,Hartmut Goldschmidt,Katja Weisel,Katja Weisel,Alessandro Rambaldi,Alessandro Rambaldi,Donna Reece,Fabio Petrocca,Monica Massaro,Jamie N Connarn,Shari Kaiser,Payal Patel,Liping Huang,Timothy B. Campbell,Kristen Hege,Jesús F. San-Miguel +30 more
TL;DR: In this article, a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expecable clinical outcomes with the use of idecabtagene vicleucel (ide-cel), also called bb2121.
Journal ArticleDOI
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
M. Mohty,Florent Malard,M. Abecassis,Erik Aerts,Ahmed Alaskar,M Aljurf,Mutlu Arat,Peter Bader,Frédéric Baron,Ali Bazarbachi,Didier Blaise,Fabio Ciceri,Selim Corbacioglu,J.-H. Dalle,Fiona L Dignan,Takahiro Fukuda,Anne Huynh,Tamás Masszi,Mauricette Michallet,Arnon Nagler,Mairead NiChonghaile,S. Okamoto,A Pagliuca,C Peters,Finn Bo Petersen,Paul G. Richardson,Tapani Ruutu,Bipin N. Savani,E. Wallhult,Ibrahim Yakoub-Agha,R. F. Duarte,Enric Carreras +31 more
TL;DR: A new definition for diagnosis, and a severity-grading system for SOS/VOD in adult patients, are proposed on behalf of the European Society for Blood and Marrow Transplantation.
Journal ArticleDOI
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Frédéric Garban,Michel Attal,Mauricette Michallet,Cyrille Hulin,Jean Bourhis,Ibrahim Yakoub-Agha,Thierry Lamy,Gerald Marit,Frédéric Maloisel,Christian Berthou,Mamoun Dib,Denis Caillot,Bernard dePrijck,Nicolas Ketterer,Jean-Luc Harousseau,Jean-Jacques Sotto,Philippe Moreau +16 more
TL;DR: In patients with high-risk de novo MM, the combination of ASCT followed by dose-reduced allogeneic transplantation was not superior to tandem dose-intensified, melphalan-based ASCT.